Posts tagged Neil Maruoka


Oncolytics Biotech Inc. (ONC) Stock Is Significantly De-Risked After End-of-Phase II Meeting with FDA, Cheers Canaccord

Analyst lifts price target on Oncolytics with new clarity from the FDA on Reolysin’s path forward to approval.

Read more

Canaccord Assumes a Speculative Buy on Aurinia Pharmaceuticals Inc (AUPH) Amid High Risk Factor for Biotech Drug Development

However, Aurinia’s not-so-secret lead drug asset Voclosporin offers a compelling partnering opportunity.

Read more

Is Valeant Pharmaceuticals Intl Inc (VRX) on the Road to Recovery?

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) posted first quarter financial results yesterday for the year that …

Read more

Valeant Pharmaceuticals Intl Inc Takes First Steps To Address Leverage: Canaccord

Canaccord analyst Neil Maruoka came out today with a few thoughts on Valeant Pharmaceuticals Intl Inc …

Read more

Canaccord Cuts Price Tag on AEterna Zentaris Inc. (USA) (AEZS) Following Doomed Macrilen Phase 3 Failure; Shares Fall 8%

AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) shares are sinking 8% after the firm announced what Canaccord …

Read more

Canaccord Weighs in on Valeant Pharmaceuticals Intl Inc (VRX) Amid Regime Turnover of High-Level Executives

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares were falling 5% yesterday after the reveal that three …

Read more

Beaten Biotech Stock in Spotlight: Valeant Pharmaceuticals Intl Inc (VRX)

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares stumbled over 10% in the past two days, after the …

Read more

Canaccord Lowers Price Target on AEterna Zentaris Inc (AEZS); Eyes Peeled to Clinical Drivers

AEterna Zentaris (NASDAQ:AEZS) delivered a financial third-quarter report on Tuesday, November 8th that “modestly” underperformed …

Read more

Canaccord Sees Valeant Pharmaceuticals Intl Inc (VRX) as Challenged for Growth

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) posted a third-quarter print yesterday that was decent in terms …

Read more

Canaccord Raises Price Target on Valeant Pharmaceuticals International, Inc. (VRX) on Back of Credit Facility Amendment

Analyst Neil Maruoka of Canaccord raised his price target on Hold-rated Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) …

Read more